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Developmental windows of susceptibility to
inorganic arsenic: a survey of current toxicologic
and epidemiologic data†
P. A. Bommaritoa and R. C. Fry*a,b
Globally, millions of people are exposed to elevated levels of inorganic arsenic (iAs) via drinking water.
Exposure to iAs is associated with a wide range of negative health outcomes, including cancers, skin
lesions, neurological impairment, cardiovascular diseases, and an increased susceptibility to infection.
Among those exposed to iAs, the developing fetus and young children represent particularly sensitive
subpopulations. Specifically, it has been noted in animal models and human populations that prenatal and
early life iAs exposures are associated with diseases occurring during childhood and later in life. Recent
epidemiologic and toxicologic studies have also demonstrated that epigenetic alterations may play a key
mechanistic role underlying many of the iAs-associated health outcomes, including the carcinogenic and
immunologic effects of exposure. This review summarizes some of the key studies related to prenatal and
early life iAs exposure and highlights the complexities in isolating the precise developmental windows of
exposure associated with these health outcomes.
Introduction
Over 100 million people, worldwide, are estimated to be
exposed to inorganic arsenic (iAs) via drinking water at levels
that exceed the World Health Organization’s (WHO)
recommended limit of 10 ppb.1,2 In addition to the massive
poisoning occurring in Bangladesh, iAs has been identified at
levels of concern in many other populations around the globe,
including the United States.2–5 Of public health concern,
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exposure to iAs at levels greater than 10 ppb has been associ-
ated with a wide range of negative health outcomes, including
cancers of the skin, bladder, liver, and lung, immunological
dysfunction, neurological impairment, increased mortality,
and complications during pregnancy.2
There is growing evidence that the developing fetus and
young children represent particularly sensitive subpopulations
at risk of the harms of exposure to iAs through drinking water.
Prenatal exposures to iAs are of concern because iAs crosses
the placental barrier and is found in the umbilical cord at
levels that are similar to those found in the mother.6
Moreover, exposures during pregnancy are associated with dis-
eases in offspring occurring during childhood and those emer-
ging later in life.7,8 There is additional evidence that early life
exposures are similarly associated with later life disease.9
Specifically, such exposures have been associated with cogni-
tive impairment, increased susceptibility to infectious dis-
eases, impaired pulmonary function, cardiovascular disease,
and cancers occurring during adulthood.10–14 In rural and
developing regions where there is a reliance upon ground-
water, rather than regulated utilities systems, pregnant women
and young children are especially at risk for exposure to elev-
ated drinking water iAs. With relevance to children’s exposure,
there is emerging evidence that rice products, which comprise
a significant proportion of many children’s diets, may rep-
resent a source of iAs exposure.15–17 Therefore, it is critical that
the risks associated with prenatal and early life iAs exposures
are thoroughly understood.
In this review, we describe current epidemiologic and toxi-
cologic data regarding health effects associated with prenatal
and early life iAs exposure. Human studies have provided evi-
dence that prenatal and early life exposures to iAs yield a range
of adverse health outcomes including cancer and non-cancer
endpoints. Here, we focus on a subset of these outcomes,
including neurodevelopmental, reproductive, and immuno-
logical endpoints, along with evidence of the epigenetic under-
pinnings of iAs-induced disease. The studies reviewed here
can be found in Tables S1 and S2. Importantly, in populations
where children experience such exposures, the timing often
occurs during the prenatal period, childhood, and adulthood.
This impairs the ability to differentiate the effects associated
with iAs exposure during specific developmental windows.
Thus, this review highlights the importance of continued
research, especially using animal models, to elucidate the
important underpinnings of these complex health outcomes
and to isolate the health effects associated with precise devel-
opmental windows of exposure.
Health effects of prenatal and early life
exposure: epidemiologic evidence
There is great interest in understanding the health effects of
prenatal and early life iAs exposure. Such exposures have been
linked, in population studies, to pregnancy complications,
adverse birth outcomes, epigenetic reprogramming, and
cancer and non-cancer outcomes appearing both during child-
hood and adulthood.7
Much of the research on iAs exposure has been focused on
its carcinogenic effects. Among the first human population-
based evidence that prenatal and early life exposure to iAs was
associated with cancers in both childhood and adulthood
comes from ecologic studies in Antofagasta, Chile.11,18,19 In
Antofagasta, exposure to high levels of iAs (approximately
870 ppb) was limited to a defined time period, specifically
1958–1971, during which the city switched to an iAs-contami-
nated drinking water source. Given that extremely high iAs
exposure occurred during a defined period of time and
impacted all individuals throughout Antofagasta, this incident
serves as a “natural experiment” in which the effects of iAs
exposure during specific developmental periods can be
studied. Utilizing mortality records from 1989–2000, research-
ers reported a significant increase in the mortality from
bladder, laryngeal, lung, kidney, and liver cancers, along with
chronic obstructive pulmonary disorders (COPD) and circula-
tory diseases in Antofagasta compared to other regions of
Chile. Specifically, such an effect was noted among residents
who were 30–49 years old and had experienced in utero and/or
childhood exposure to the iAs-contaminated drinking water.11
These findings have been critical in establishing the latent
effects of prenatal and early life iAs exposure. While it is
difficult to isolate in utero from early life exposure, these
results set the stage for continuing research into these latent
effects.
Evidence that early life exposures could be associated with
other latent and persistent effects occurred following the
Morinaga dried milk poisoning in Japan in the 1950s. In this
incident, infant formula was contaminated with approximately
4000–7000 ppb of iAs, corresponding to a daily dose of over
500 μg per kg body weight.20 During the poisoning, high
numbers of infants suffering symptoms of acute iAs toxicity
were reported and more than a hundred infants died.
However, among those that survived, there is evidence
suggesting that iAs exposure is associated with a range of
neurological effects, including epilepsy, lower Intelligence
Quotients (IQ), and higher rates of severely impaired neuro-
development (IQ < 50).20,21 Unfortunately, the response to this
incident did not include measuring internal iAs doses in
affected children or establishing follow-up. Therefore, ground-
work was not laid for more rigorous studies on the effects of
acute iAs exposure during infancy.20
More recent studies have been conducted to establish the
neurodevelopmental effects of iAs at much lower doses than
those experienced by infants during the Morinaga, Japan dried
milk poisoning. Numerous studies have demonstrated an
inverse relationship between neurodevelopmental measures
and iAs exposure.22–24 For instance, using modified IQ tests in
the Maternal and Infant Nutrition Intervention in Matlab
(MINIMat) cohort in Bangladesh, researchers estimated that
maternal and/or early childhood urinary iAs measures of
100 ppb are associated with a loss of 1–3 IQ points in Verbal
and Full Scale IQ measures at 5 years of age. Interestingly, this
Review Toxicology Research
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association was only significant for girls, but was seen with
respect to iAs exposures occurring during early gestation, late
gestation, and childhood.25 Previous studies emerging from
this population have not observed significant neurodevelop-
mental changes at time-points prior to 5 years of age,
suggesting that these effects may emerge later in develop-
ment.26 In Maine, a cross-sectional study demonstrated that
drinking well water with ≥5 ppb iAs was associated with a loss
of 4–6 IQ points in Full Scale IQ and in the index scores for
Perceptual Reasoning, Working Memory, and Verbal
Comprehension, even after adjustment for covariates.27
However, unlike the Morinaga dried milk poisoning in Japan,
the populations under study did not have exposure that was
limited to a single developmental window. As a result,
researchers have not been able to isolate the effects of iAs
exposure to a precise developmental window in humans.
Nevertheless, these studies provide consistent evidence that
prenatal and early life iAs exposure is associated with impaired
neurodevelopment.
iAs-induced immunomodulatory effects are believed to
underlie many iAs-associated health outcomes.28 Disrupted
immune functioning has been noted in adult populations with
chronic iAs exposure.29,30 With respect to early life exposures,
research from the New Hampshire Birth Cohort, a prospective
pregnancy cohort of women on private well water systems, pro-
vides evidence for similar outcomes in infants. In pregnant
women exposed to low levels of iAs (average drinking water iAs
level of 5.2 ppb), maternal urinary iAs was positively associated
with infections in infants. In particular, prenatal iAs measures
were associated with lower respiratory tract infections requir-
ing prescriptions, and non-significantly associated with respir-
atory symptoms, upper respiratory infections, diarrhea symp-
toms, and infections in the first four months of life requiring
a doctor’s visit.31 Updated results from this cohort show that
these relationships persist at one year of age.32 Similar evi-
dence has also been reported in multiple Bangladeshi
cohorts.13,33,34 Again, it was not possible to pinpoint exposures
that occurred only during the prenatal period, although there
is evidence that ingested forms of iAs did not contribute sig-
nificantly to iAs exposure during infancy.35 Taken together,
these results suggest that prenatal iAs is associated with
impaired immunodevelopment. This is supported by mole-
cular evidence demonstrating that prenatal iAs exposure is
associated with disruptions in the expression of inflammatory-
related genes, secretion of immune-mediating molecules, and
shifts in lymphocyte subpopulations.36–40
With respect to reproductive outcomes, there is accumulat-
ing evidence that in utero iAs exposure is associated with
adverse pregnancy outcomes, including miscarriage, fetal
growth restriction, and gestational diabetes.41–44 It has been
demonstrated in several populations that prenatal iAs exposure
is also associated with birth outcome measurements, includ-
ing birth weight, head circumference and birth length.41,45–49
Specifically, in the Biomarkers of Exposure to ARsenic (BEAR)
pregnancy cohort of women living in an iAs endemic region of
Mexico, every one-unit increase in the percent of maternal
urinary monomethylated arsenicals (%MMAs) correlated to a
decrease of 24.4 grams in birth weight.46 Exposure to MMAs,
specifically, has also been linked to low birth weight in other
populations.45,46 Changes in such birth outcomes are signi-
ficant given they may be early indicators of childhood IQ.50,51
At the molecular level, prenatal iAs exposure has been
associated with large-scale gene expression changes in a popu-
lation of iAs exposed infants in Thailand. In particular, path-
ways associated with inflammation and the nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB)
cascade were disrupted in association with iAs exposure corres-
ponding to drinking water levels above the WHO 10 ppb rec-
ommended exposure limit.36 In Bangladesh and Mexico,
increases in protein expression of pro-inflammatory markers,
including cytokines, have also been observed.52,53 These tran-
scriptomic and proteomic shifts in infants suggest that epige-
netic mechanisms may control the response to prenatal and
early life iAs exposure. Supporting this, in Bangladesh, it has
been shown that prenatal iAs exposure is associated with
changes in CpG methylation in genes enriched for functions
specific to iAs-associated health outcomes, including those
related to diabetes, immune functioning, cardiovascular out-
comes, and cancer.54 Moreover, there is evidence from the
BEAR pregnancy cohort that suggests a role for both CpG
methylation and miRNAs in the response to in utero iAs
exposure. First, it was observed that newborn cord blood CpG
methylation was significantly associated with drinking water
iAs. This change in CpG methylation directly corresponded to
functional changes in gene expression for a subset of genes
with differential methylation. Moreover, several of these differ-
entially methylated genes were significantly associated with
birth weight, providing molecular-level evidence for the
relationship between iAs and birth weight.55 Second, miRNA
expression was increased in the cord blood of these infants in
association with prenatal exposure. These miRNAs were pre-
dicted to target 20% of the dysregulated gene expression
observed in this population.37 While there is not complete
overlap between the specific dysregulated genes and epigenetic
markers across each of these populations, this research has
highlighted that iAs exposure leads to epigenetic reprogram-
ming and dysregulated gene expression patterns, which may
influence health outcomes in these populations and inform
future mechanistic studies.
Using human studies to discern the precise developmental
windows during which exposure yields specific iAs-associated
diseases has obvious limitations. Even among studies where
researchers can estimate prenatal or childhood exposures, it is
often difficult to take into account exposures occurring during
other developmental windows. This poses complications for
the field, especially when considering the long latency of many
iAs-associated health outcomes. As a result, there are wide
gaps in our understanding of both the doses and developmen-
tal windows of exposure that yield such outcomes. Moreover,
the ability to investigate the mechanisms underlying the wide
array of iAs-associated diseases is limited in human studies.
Such limitations underscore the need for animal models in
Toxicology Research Review
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the study of iAs-induced disease. This is particularly important
given the large populations of pregnant women and children
at risk for elevated exposure across the world.
Health effects of prenatal and early life
exposure: in vivo evidence
Due to metabolic differences between rodents and humans,
there have been difficulties in establishing an animal model to
investigate the various carcinogenic effects of iAs exposure.56
However, mouse models using a prenatal and a “whole-life”
exposure paradigm have been successfully established, allow-
ing in vivo mechanistic studies of iAs-induced cancers.57,58 The
successes associated with using mouse models that include
in utero exposure, but not those without, demonstrates the sen-
sitivity of the prenatal period.
The prenatal exposure paradigm has been used to establish
that prenatal iAs exposure is associated with several different
types of cancers in adulthood. Following an exposure to 42.5
or 85 ppm NaAsO2, from gestational day 8–18, offspring deve-
loped cancer at an increased incidence and multiplicity com-
pared to controls. Interestingly, sex-specific effects were noted,
with hepatocellular carcinomas and adrenal tumors in males,
and cancers of the reproductive tract in females.59 Offspring
were also topically exposed to the tumor promotor 12-O-tetra-
decanoyl phorbol-13-acetate (TPA), which promoted iAs-
induced liver tumors in females and lung tumors in both
males and females.59 Other research using this exposure para-
digm demonstrated that prenatal exposure to 12.5 or 25 ppm
of the trivalent monomethylated arsenical, methylarsonous
acid (MMAsIII), induces many of the same lesions noted in
iAs-exposed mice above, in a dose-dependent manner.60
However, transplacental exposure to MMAsIII also induced
rarer testicular lesions, including interstitial and rete testis
adenomas and hyperplasias.60 These results may indicate that
MMAsIII is uniquely toxic, inducing different effects than
iAs or other methylated iAs metabolites. This evidence mirrors
observations in human populations where higher measures of
urinary MMAs are associated with increased risks of
cancers, skin abnormalities, chromosomal aberrations,
and peripheral vascular disease, as reviewed by Tseng.61
Additionally, as mentioned previously, %MMAs has been
associated with a reduction in birth weight in infants with
prenatal iAs exposure.46 Together, these results suggest that
MMAs may be more toxic compared to iAs and other iAs
metabolites.
The prenatal exposure paradigm has also been used to
provide mechanistic evidence for iAs-associated health effects.
In particular, prenatal exposure to 85 ppm of NaAsO2 has been
noted to induce changes in methylation status of GC rich
regions of hepatocellular DNA in C3H mice, along with an
induction of glutathione system genes and metallothionein-1,
a reduction in the expression of genes involved in methyl
metabolism and the tumor suppressor gene p16, and disrup-
tion in CYP450s and insulin-like growth factor genes.62 There
is additional evidence that prenatal iAs exposure in male mice
yields a 90% decrease in methylation of the estrogen
receptor-α (ER-α) promoter, corresponding to a 3.1-fold
increase in the expression of ER-α in iAs-induced hepatocellu-
lar carcinoma.63 These findings provide evidence for the
theory that epigenomic alterations may underlie the carcino-
genic effects of iAs, providing a sustained reprogramming of
cellular behavior necessary for the latency of many iAs-associ-
ated cancers.
Notably, the exposures required to study iAs-induced
cancers in a prenatal mouse model are well above most upper
limits of human exposure.57–60,62,64,65 One of the reasons for
the use of high doses is the observation that rodents are rela-
tively resistant to iAs exposure compared to human popu-
lations.65 Moreover, while a prenatal model is necessary to
accurately determine which health outcomes are specifically
associated with the prenatal exposure window, it often does
not accurately reflect human exposures. Using a “whole-life”
exposure paradigm, where CD1 mice were exposed to 50, 500,
or 5000 ppb throughout gestation, adolescence, and adult-
hood, it has been demonstrated that exposures primarily in
the 50 and 500 ppb range, but not 5000 ppb, are associated
with lung cancers in both male and female mice.64 In males,
exposures in this range were associated with an increase in
bronchiolo-alveolar tumors, while an increase in lung adeno-
mas was observed in female mice.64 These results correspond
to evidence that suggests that iAs may serve as a chemothera-
peutic at higher doses, but can be tumorigenic at lower
doses.64,66 The “whole-life” exposure paradigm has also been
used to demonstrate that there is an overabundance of cancer
stem cells (CSCs) in hepatocellular carcinomas and lung ade-
nocarcinomas in CD1 mice exposed to 6, 12, or 24 ppm
NaAsO2, suggesting that iAs leads to the formation of CSCs in
iAs-induced cancers.58 Again, such findings present a possible
explanation for the long latency associated with iAs-induced
cancers by providing evidence for a population of cells that
can remain quiescent following initiation.67 Large populations
of CSCs have also been noted in other iAs-exposed animal
models and iAs-transformed cell lines, providing further
evidence of the role of CSCs in iAs-induced cancers.68–70
Moreover, many of the cancers identified using the “whole-
life” exposure paradigm match, or are similar, to those identi-
fied in the prenatal mouse models, indicating that trans-
placental exposure may determine the target sites for
carcinogensis.58
Aside from the carcinogenic effects of iAs exposure, pre-
natal and “whole-life” exposure paradigms have been employed
to study other iAs-associated health effects, including cardio-
vascular, pulmonary, neurodevelopmental, metabolic, and
reproductive effects, among others.71–75 For instance, a recent
study using a transplacental exposure paradigm found that
exposure during the second half of gestation to iAs levels as
low as 10 ppb was associated with increased body weight,
impaired glucose tolerance and earlier onset of vaginal
opening, an indicator of puberty, compared to controls.74
Notably, effects were seen at much lower levels than those
Review Toxicology Research
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required to investigate cancer outcomes in mice. However, the
range of iAs-associated health outcomes that can be investi-
gated using these exposure paradigms remains unclear. While
mouse models allow researchers to isolate the precise windows
of susceptibility associated with specific health outcomes, they
may not offer a complete picture with respect to determining
the doses at which these outcomes are observed in human
populations, particularly for cancer outcomes. This is the
result of metabolic differences between humans and mouse
models, rendering humans more sensitive to iAs exposure.
Nevertheless, these models provide valuable mechanistic data
that is unobtainable from current human studies and demon-
strates the ongoing need for animal research when studying
the effects of prenatal and early life exposure to iAs.
Discussion and conclusions
iAs contaminated drinking water represents a global problem,
putting developing fetuses and young children at risk of
experiencing adverse health outcomes as the result of
exposure. As the “natural experiment” in Antofagasta, Chile
and the Morniaga, Japan dried milk poisoning incidents
demonstrate, iAs exposure in utero and during early childhood
is associated with unique health outcomes compared to
exposures occurring during adulthood. These populations
demonstrate the sensitivity of the prenatal and early life devel-
opmental periods and indicate that developing fetuses and
young children are particularly at risk for disease associated
with iAs exposure. However, these scenarios also represent
some of the few situations in which it is possible to definitively
isolate iAs exposure to specific developmental periods.
Therefore, the need for animal models remains. Mouse
models, including the prenatal and “whole-life” models better
enable researchers to separate the effects associated with pre-
natal exposure from those associated with early life exposures.
By using these exposure paradigms, the transplacental and
early life effects of iAs can be more clearly differentiated.
Additionally, sex-dependent effects have been noted for iAs
exposure in both human populations and mouse models.
These results demonstrate that the sex of the infant influences
the outcomes experienced following iAs exposure. As men-
tioned above, results from the MINIMat cohort demonstrate
that IQ in females is significantly inversely associated with iAs
exposure, but not in males.25 Research from Antofagasta, Chile
also demonstrates that the risk of cancer and non-cancer out-
comes tends to be greater for males than for females.11 In
mouse models, some tumors are noted to be increased in inci-
dence and multiplicity in both genders. However, in several
studies, sex-dependent tumor locations have also been noted
and provide more evidence that iAs acts in a sex-dependent
manner.57–60,64 Again, the prenatal and “whole-life” exposure
paradigms allow for closer examination of the mechanisms
driving such effects.
Despite the advances made in understanding the prenatal
and early life effects of iAs exposure using available epidemiolo-
gic data and mouse models, important gaps in understanding
remain. In particular, the dose ranges required for specific iAs-
associated health outcomes have yet to be determined. For
instance, the epidemiologic evidence for the neurodevelopmen-
tal impacts of iAs provides a mixed picture for the doses yielding
a decrease in IQ in children. In the MINIMat cohort, where
drinking water iAs is well above 10 ppb, the effect size reported
estimates that a urinary iAs level of 100 ppb corresponds to a
loss of 1–3 Full Scale IQ and Verbal IQ points in exposed
children.25 However, in Maine, exposure to drinking water levels
greater than only 5 ppb iAs is associated with a decrease of 5–6
Full Scale IQ, Verbal Comprehension, Working Memory, and
Perceptual Reasoning IQ points in children.27 The disparity in
these results may be related to several factors, including (1) nutri-
tional differences between these populations,76 (2) potential
differences in susceptibility between populations with respect to
the particular effects of iAs,77 and possibly (3) difficulties in
quantifying and comparing neurodevelopmental indicators,
such as IQ, between different populations. The differences
between the magnitude of these effects and possible underlying
factors represent the challenge presented by identifying the criti-
cal dose ranges for iAs-associated health outcomes.
Unfortunately, due to the differences in sensitivity to iAs
between humans and mouse models, there are complexities in
extrapolating dose–response relationships between mice and
humans, particularly for the carcinogenic effects of iAs.65
Currently, the exposures required to induce cancers in mouse
models, particularly using the prenatal exposure paradigm,
often exceed those identified in human populations due to
their relative resistance to iAs.64,65 Thus, the current approach
may be insufficient for defining these critical dose ranges.
As discussed by Waalkes et al.,65 the assumption cannot be
made that equivalent drinking water exposures translates to
equivalent internal doses for humans and mice. Instead,
researchers should compare the amount of iAs that accumu-
lates within target tissues, rather than comparing the levels of
exposure between humans and mouse models. Such an
approach may allow mouse models to be used more efficiently
to study iAs-associated health effects and to determine the
critical dose ranges responsible for iAs-induced disease.
Additionally, there is emerging evidence that epigenetic
reprogramming may underlie the outcomes associated with
iAs exposure. Epidemiologic evidence has contributed to this
by demonstrating that both CpG methylation and miRNA
expression are associated with iAs exposure in human popu-
lations. Moreover, a few studies demonstrate that these epi-
genetic markers correspond to functional changes in gene
expression and represent a possible mechanism for iAs to
reprogram cellular activities in a sustained manner, providing
an explanation for the long latency periods between prenatal
and early life exposures and adult-onset diseases.37,54,55 Given
the promise of inquiry into epigenetic mechanisms underlying
iAs-induced effects, this research should be further expanded
using animal models.
Looking forward, if iAs-induced diseases are epigenetically
driven, it is possible that interventions may successfully
Toxicology Research Review
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prevent the sustained cellular reprogramming observed follow-
ing prenatal and early life iAs exposure, thereby protecting
against iAs-induced disease. To date, nutritional interventions
on iAs exposure have primarily focused on ensuring that nutri-
tional deficiencies do not impede iAs metabolism.76,78,79
However, the reversibility of epigenetic programming implies
that nutritional interventions may also have the potential to
alter the epigenetic dysregulation induced by iAs exposure.80
Therefore, understanding the mechanisms underlying iAs-
induced disease and the precise windows of developmental
susceptibility in which they are observed is of great public
health importance.
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